Evidence map›Paper›PMID 39994010›Full record

ArticleAnti-cancer agents in medicinal chemistry2025

Recurrent Missense Driver STAT5B

Rehana Yasmin, Rashda Abbasi, Tajdar Jahangir Gohar, Hina, Nafees Ahmad, Sajid Malik

Abstract read
PubMed Publisher
In one paragraph

Article in Anti-cancer agents in medicinal chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Rehana YasminInstitute of Biomedical and Genetic Engineering, Islamabad, 44000, Pakistan.
Rashda AbbasiInstitute of Biomedical and Genetic Engineering, Islamabad, 44000, Pakistan.
Tajdar Jahangir GoharDepartment of Pharmacy, COMSATS University, Islamabad, Abbottabad Campus, Abbottabad, 22044, Pakistan.
HinaSarhad Institute of Allied Health Sciences, Faculty of Life Sciences, Sarhad University of Science and Technology, Peshawar, 25000, Pakistan.
Nafees AhmadInstitute of Biomedical and Genetic Engineering, Islamabad, 44000, Pakistan.
Sajid MalikDepartment of Zoology, Human Genetics Program, Faculty of Biological Sciences, Quaid-I-Azam University, Islamabad, 45320, Pakistan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe occurrence of gain of function mutations in STAT5B has been associated to survival, and drug resistance in Leukemia.

objectiveThis study was designed to screen selected

methodsIn total 276 patients were randomly recruited for this study. Demographic and clinical data were summarized. The genetic status of JAK1

resultsAcute lymphoblastic leukemia comprises 70% of the total patients. Male to female ratio was 3:1. All the patients were homozygous for JAK1

conclusionThe aggressive form of pediatric leukemia, carrying STAT5B

Indexed as

Antineoplastic AgentsMutation, MissensePrecursor Cell Lymphoblastic Leukemia-LymphomaSTAT5 Transcription FactorAdolescentCell ProliferationChildChild, PreschoolDose-Response Relationship, DrugDrug Screening Assays, AntitumorFemaleHumansMaleMolecular Docking SimulationMolecular StructureStructure-Activity RelationshipAntineoplastic AgentsSTAT5B protein, humanSTAT5 Transcription FactorAC-4-130aggressive leukemiapersonalized therapystafib-2.STAT5BN642Htargeted inhibition

Identifiers

PMID39994010

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.